Impact of pharmacologic interventions-treating endothelial dysfunction and group 2 pulmonary hypertension

Marco Guazzi, Mardi Gomberg-Maitland, Robert Naeije

Research output: Contribution to journalArticle

Abstract

Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging preliminary data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.

Original languageEnglish
Pages (from-to)473-479
Number of pages7
JournalProgress in Cardiovascular Diseases
Volume57
Issue number5
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Pulmonary Hypertension
Heart Failure
Vasodilator Agents
Lung
Heart Diseases
Pharmacology
Population
Phosphodiesterase 5 Inhibitors
Endothelin Receptors
Heart-Assist Devices
Guanylate Cyclase
Natural History
Hypotension
Prostaglandins
Chronic Disease
Transplants
Liver
Therapeutics

Keywords

  • Endothelin-1 receptor blockers
  • Guanylate cyclase stimulators
  • Heart failure
  • Nitric oxide
  • PDE-5 inhibitors
  • Prostaglandins
  • Pulmonary hypertension
  • Pulmonary vasodilators

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of pharmacologic interventions-treating endothelial dysfunction and group 2 pulmonary hypertension. / Guazzi, Marco; Gomberg-Maitland, Mardi; Naeije, Robert.

In: Progress in Cardiovascular Diseases, Vol. 57, No. 5, 01.03.2015, p. 473-479.

Research output: Contribution to journalArticle

@article{c3c9e6fb22774b73940bc99d19ce2e58,
title = "Impact of pharmacologic interventions-treating endothelial dysfunction and group 2 pulmonary hypertension",
abstract = "Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging preliminary data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.",
keywords = "Endothelin-1 receptor blockers, Guanylate cyclase stimulators, Heart failure, Nitric oxide, PDE-5 inhibitors, Prostaglandins, Pulmonary hypertension, Pulmonary vasodilators",
author = "Marco Guazzi and Mardi Gomberg-Maitland and Robert Naeije",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.pcad.2014.11.002",
language = "English",
volume = "57",
pages = "473--479",
journal = "Progress in Cardiovascular Diseases",
issn = "0033-0620",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Impact of pharmacologic interventions-treating endothelial dysfunction and group 2 pulmonary hypertension

AU - Guazzi, Marco

AU - Gomberg-Maitland, Mardi

AU - Naeije, Robert

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging preliminary data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.

AB - Pulmonary hypertension (PH) secondary to left heart disease (LHD) is a largely underappreciated therapeutic target. Except for a specific focus on PH consequences in patients with advanced heart failure (HF) receiving a left ventricular assist device or candidates for heart transplant, prevention and treatment of initial subclinical forms of PH are not considered a priority in the management of this chronic disease population. Nonetheless, there is recent growing evidence supporting a clinical and prognostic role of PH in the elderly populations and in HF with preserved ejection fraction (pEF). Although the prevalence of PH in these populations still remains largely unknown, there is a large potential for effective pharmacological approaches that might impact the natural history of HFpEF by targeting earlier stages. However, pharmacological studies performed to date with traditional pulmonary vasodilators (i.e. prostanoids and endothelin receptor blockers) in cohorts with HF and left-sided PH have not been positive, primarily because of concomitant systemic hypotension and hepatic toxicity. The encouraging preliminary data with more selective well-tolerated pulmonary vasodilators, such as phosphodiesterase type 5 inhibitors and guanylate cyclase stimulators/activators, however, suggest the need for new targets of pulmonary microvascular dysfunction and for treating PH-LHD at both early and later stages of the disease process.

KW - Endothelin-1 receptor blockers

KW - Guanylate cyclase stimulators

KW - Heart failure

KW - Nitric oxide

KW - PDE-5 inhibitors

KW - Prostaglandins

KW - Pulmonary hypertension

KW - Pulmonary vasodilators

UR - http://www.scopus.com/inward/record.url?scp=84924806894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924806894&partnerID=8YFLogxK

U2 - 10.1016/j.pcad.2014.11.002

DO - 10.1016/j.pcad.2014.11.002

M3 - Article

C2 - 25446553

AN - SCOPUS:84924806894

VL - 57

SP - 473

EP - 479

JO - Progress in Cardiovascular Diseases

JF - Progress in Cardiovascular Diseases

SN - 0033-0620

IS - 5

ER -